Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 1974-1980

  Abate, Davide ^a   Fiscon, Marta ^a   Saldan, Alda ^a   Cofano, Simona ^a   Mengoli, Carlo ^a   Sgarabotto, Dino ^a   D'Agostino, Chiara ^a   Barzon, Luisa ^a   Cusinato, Riccardo ^a   Toscano, Giuseppe ^a   Feltrin, Giuseppe ^a   Gambino, Antonio ^a   Gerosa, Gino ^a   Palù, Giorgio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; VIRUS DNA;

ADULT; AGED; ARTICLE; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; IMMUNOMODULATION; INCIDENCE; INFECTION CONTROL; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PATIENT CODING; PATIENT IDENTIFICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; SERODIAGNOSIS; VIREMIA; VIRUS REPLICATION;

ADULT; AGED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEART DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK ASSESSMENT; T-LYMPHOCYTES; VIRAL LOAD; VIREMIA;

HUMAN HERPESVIRUS 5;

EID: 84862075982     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.06406-11     Document Type: Article

References (46)

1. Abate D, et al. 2012. Diagnostic utility of human cytomegalovirus- specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation 93:536-542.
2. Abate D, et al. 2010. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J. Infect. Dis. 202:585-594.
3. Baldanti F, Lilleri D, Gerna G. 2008. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41:237-241.
4. Bunde T, et al. 2005. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med. 201:1031-1036. (Pubitemid 40524670)
5. Cummins NW, Deziel PJ, Abraham RS, Razonable RR. 2009. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl. Infect. Dis. 11:20-27.
6. Dumortier J, et al. 2008. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J. Virol. 82:6524-6535. (Pubitemid 351875129)
7. Dunn HS, et al. 2002. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J. Infect. Dis. 186:15-22. (Pubitemid 34666909)
8. Epstein SE, et al. 1996. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 348(Suppl 1):s13-s17.
9. Fateh-Moghadam S, et al. 2003. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 76: 1470-1474. (Pubitemid 37467696)
10. Fearon WF, et al. 2007. Changes in coronary arterial dimensions early after cardiac transplantation. Transplantation 83:700 -705.
11. Feuchtinger T, et al. 2010. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116:4360-4367.
12. Fisher RA. 2009. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl. Infect. Dis. 11:195-202.
13. Fishman JA. 2007. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357:2601-2614. (Pubitemid 350294226)
14. Gerna G, Lilleri D. 2006. Monitoring transplant patients for human cytomegalovirus: diagnostic update. Herpes 13:4-11. (Pubitemid 43900947)
15. Gerna G, et al. 2006. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant. 6:2356-2364. (Pubitemid 44359421)
16. Gredmark S, Jonasson L, Van Gosliga D, Ernerudh J, Soderberg- Naucler C. 2007. Active cytomegalovirus replication in patients with coronary disease. Scand. Cardiovasc. J. 41:230-234. (Pubitemid 47261203)
17. Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. 2008. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes 15:4-12.
18. Hunt SA, Haddad F. 2008. The changing face of heart transplantation. J. Am. Coll. Cardiol. 52:587-598.
19. Kern F, et al. 2002. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis. 185:1709-1716. (Pubitemid 34615463)
20. Kirchner A, et al. 2008. Dissection of the CMV specific T-cell response is required for optimized cardiac transplant monitoring. J. Med. Virol. 80: 1604-1614.
21. Kotton CN. 2010. Management of cytomegalovirus infection in solid organ transplantation. Nat. Rev. Nephrol. 6:711-721.
22. Legendre C, Pascual M. 2008. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin. Infect. Dis. 46:732-740. (Pubitemid 351321558)
23. Maecker HT, et al. 2008. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 9:9.
24. McLaughlin-Taylor E, et al. 1994. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J. Med. Virol. 43:103-110. (Pubitemid 24146353)
25. Mengoli C, et al. 2004. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. J. Med. Virol. 74:78-84. (Pubitemid 38988863)
26. Micklethwaite KP, et al. 2008. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 112:3974-3981.
27. Mocarski ES, Shenk T, Pass RF. 2001. Cytomegaloviruses and their replication, p 2629-2673. In Knipe DM, Howley PM (ed), Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA.
28. Paya CV. 1999. Indirect effects of CMV in the solid organ transplant patient. Transpl. Infect. Dis. 1(Suppl 1):8-12.
29. Paya CV. 2001. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin. Infect. Dis. 32:596-603. (Pubitemid 32565001)
30. Potena L, et al. 2003. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 75:839-843. (Pubitemid 36378122)
31. Potena L, et al. 2006. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82:398-405. (Pubitemid 44223041)
32. Potena L, Valantine HA. 2007. Cardiac allograft vasculopathy and insulin resistance-hope for new therapeutic targets. Endocrinol. Metab. Clin. North Am. 36:965-981, ix. (Pubitemid 350026261)
33. Razonable RR. 2005. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am. J. Health Syst. Pharm. 62:S7-S13. (Pubitemid 40547355)
34. Rubin RH. 2002. Overview: pathogenesis of fungal infections in the organ transplant recipient. Transpl. Infect. Dis. 4(Suppl 3):12-17. (Pubitemid 34832431)
35. Rubin RH. 1991. Preemptive therapy in immunocompromised hosts. N. Engl. J. Med. 324:1057-1059.
36. Rubin RH, Schaffner A, Speich R. 2001. Introduction to the Immuno-compromised Host Society Consensus Conference on Epidemiology, Prevention, Diagnosis, and Management of Infections in Solid-Organ Transplant Patients. Clin. Infect. Dis. 33(Suppl 1):S1-S4. (Pubitemid 32554478)
37. Schmidt GM, et al. 1991. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. The City of Hope-Stanford-SyntexCMV Study Group. N. Engl. J. Med. 324:1005-1011.
38. Sester U, et al. 2005. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am. J. Transplant. 5:1483-1489. (Pubitemid 40839442)
39. Stewart S, et al. 2005. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24:1710-1720. (Pubitemid 41641841)
40. Taylor DO, et al. 2009. Registry of the International Society for Heart and Lung Transplantation: Twenty-Sixth Official Adult Heart Transplant Report-2009. J. Heart Lung Transplant. 28:1007-1022.
41. Tu W, et al. 2006. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 114:1608-1615. (Pubitemid 44547431)
42. Valantine H. 2004. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J. Heart Lung Transplant. 23:S187-S193. (Pubitemid 38496395)
43. Valantine HA. 2004. The role of viruses in cardiac allograft vasculopathy. Am. J. Transplant. 4:169-177. (Pubitemid 38248518)
44. Vamvakopoulos J, Hayry P. 2003. Cytomegalovirus and transplant arteriopathy: evidence for a link is mounting, but the jury is still out. Transplantation 75:742-743. (Pubitemid 36373440)
45. Weill D. 2001. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl. Infect. Dis. 3(Suppl 2):44-48. (Pubitemid 34073656)
46. Wills MR, et al. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569 -7579.